From Pig to Patient: XenoTherapeutics Completes First Cohort of Patients in First US Clinical Trial of Live-Cell Xenotransplant; Evidence of Safety and Efficacy Allows for Accelerated Patient Enrollment BOSTON, MA, Nov. 05, 2020 (GLOBE NEWSWIRE) -- XenoTherapeutics, a clinical-stage cell and gene therapy company engineering immune-compatible cells, tissues, and organs, has completed the first of...

XenoTherapeutics Granted U.S. Patent Covering Method of Producing Clinically Acceptable Porcine Cells, Tissues, and Organs for Human Xenotransplantation BOSTON, MA, Oct. 15, 2020 (GLOBE NEWSWIRE) -- XenoTherapeutics, a clinical-stage cell and gene therapy company engineering immune-compatible cells, tissues, and organs, announced that the U.S....

XenoTherapeutics Welcomes Michael Yaremchuk as Chief Medical Officer Boston, Feb. 26, 2020 (GLOBE NEWSWIRE) -- XenoTherapeutics, a clinical-stage biotechnology company developing alternative gene therapies in xenotransplantation to supply living cells, tissues, and...